Johnson & Johnson company Janssen Research & Development has signed an agreement with Atropos Health to aid in expediting clinical development by leveraging real-world data analysis.
As part of the deal, data researchers from both companies will leverage the software platform of Atropos to assess the real-world data sets of Janssen.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This approach will aid the companies in obtaining insights into clinical development strategies.
These strategies comprise trial design optimisation, comprehending the natural history of the patients and evaluating outcomes in real-world patients.
A wide-ranging portfolio of therapeutic fields will be part of the new alliance.
Atropos Health CEO and co-founder Dr Brigham Hyde said: “Atropos Health’s core mission is to close the evidence gap for patients worldwide.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are thrilled to collaborate with Janssen R&D’s world-class data scientists to support efforts to generate insights that could help optimise and accelerate clinical trials.”
Atropos Health focuses on generating evidence for research and clinical purposes using technology. This approach aids in expediting clinical development and cutting down on time to value.
The company’s Atropos Evidence Platform is leveraged by healthcare companies and life science companies, among others, to bridge the gaps in evidence generation.
This platform also aids enterprises in boosting clinical outcomes and speeding up research activities.
Atropos’ solutions are based on numerous peer-reviewed publications, clinician users, years of clinical usage and expertise.
